Unichem Labs spurts on USFDA nod for psoriasis drug : vimars

Unichem Labs spurts on USFDA nod for psoriasis drug


Unichem Laboratories surged 5.71% to Rs 323.05 after the company received United States Food and Drug Administration (USFDA) approval for apremilast tablets, 10 mg, 20 mg and 30 mg.
The drug is a generic version of Amgen's Otezla (apremilast) tablets, 10 mg, 20 mg, and 30 mg.
The drug is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
The scrip extended gains for third day. The stock has added 6.67% in three sessions from its recent closing low of Rs 302.85 recorded on 16 February 2021.
In the past three months, the stock has added 36.73% while the benchmark Sensex has added 17.55% during the same period.

Related Keywords

United States , Amgen Otezla , Drug Administration , Unichem Laboratories , United States Food , Capital Market , Drugs , Branches Of Biology , Apremilast , Mg Cars , Medroxyprogesterone Acetate , Magnesium In Biology , Pharmaceutical , Pharmaceutical Formulations , S Ampp Bse Sensex Index , United States Food And Drug Administration , Severe Plaque , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது மாநிலங்களில் உணவு , மூலதனம் சந்தை , மருந்துகள் , கிளைகள் ஆஃப் உயிரியல் , மிகி கார்கள் , வெளிமம் இல் உயிரியல் , மருந்து , மருந்து சூத்திரங்கள் , கடுமையானது தகடு ,

© 2025 Vimarsana